Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19363854 | 0.92 | RET (0.45) | RETAURKAAURKB | |
| SCHEMBL19823168 | 0.90 | RET (0.51) | RETAURKAAURKBSYK | |
| SCHEMBL19813620 | 0.90 | RET (0.51) | RETAURKAAURKBSYK | |
| SCHEMBL18789241 | 0.85 | RET (0.55) | RETAURKAAURKBSYK | |
| SCHEMBL18789278 | 0.85 | RET (0.55) | RETAURKAAURKBSYK | |
| SCHEMBL30401442 | 0.85 | RET (0.55) | RETAURKAAURKBSYK | |
| SCHEMBL18789285 | 0.85 | RET (0.51) | RETAURKAAURKBSYK | |
| SCHEMBL18789286 | 0.85 | RET (0.51) | RETAURKAAURKBSYK | |
| SCHEMBL29969423 | 0.85 | RET (0.54) | RETAURKAAURKBSYK | |
| SCHEMBL19349943 | 0.83 | RET (0.46) | RETAURKAAURKBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035789-B2 | Compounds useful for treating disorders related to RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018022761-A1 | SUBSTITUTED CYCLOPENTANE-AMIDES FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | BLUEPRINT MEDICINES CORPORATION | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035789-B2 | Compounds useful for treating disorders related to RET | RET, EYA2, HRAS | RET 1/4885AURKA 4348/4885AURKB 3696/4885 |
| US-20180030032-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO RET | RET, EYA2, HRAS | RET 1/4885AURKA 4348/4885AURKB 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.